Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The company buys in a PI3Kα and mTOR combo.
Gilead opting against IDE397 is still good news for Ideaya.
Progression-free and overall survival data from Companion-002 are due this quarter.
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
JSKN027 will become the first ADC with this mechanism to enter human trials.
